21

KeyMed Biosciences IncHKG 2162 Stock Report

Last reporting period 30 Jun, 2022

Updated 30 Oct, 2024

Last price

Market cap $B

1.255

Small

Exchange

XHKG - Hong Kong Exchange

View Section: Price ratios

KeyMed Statements

21

Data from KeyMed`s earning releases including common size income statement and balance sheet.

Common size analysis evaluates financial statements by expressing each line item as a percentage of a base amount for that period.

Key Information:

Report currency:

CNY - Chinese yuan

Last reporting period:

30 Jun, 2022

Next reporting period:

27 Dec, 2022

Report frequency:

Semi-annual

Earnings release date:

Expected release date:

22 Aug, 2024

KeyMed Income Statement


Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

B

M

CNY (except Earnings per share)

Financial

Revenue


Cost of sales


Gross profit


Research and development


Selling, general and administrative


Total operating expenses


Operating income


Interest expense


Other income


Income before tax


Provision for income taxes


Net income


Diluted earnings per share


Shares outstanding after dilution


2022-06-30
%

100

-9.3 %

100

2.537

2.5

97.463

4.7 %

97.5

164.01

164

51.048

51

201.75

-43.3 %

201.8

-104.29

60.3 %

-104.3

106.82

106.8

0

2.524

101 %

2.5

0

5.454

102.1 %

5.5

0.02

267.34

2021-12-31
%

110.27

100

17.2

15.6

93.069

84.4

167.09

151.5

65.618

59.5

355.86

-90.1 %

322.7

-262.79

92.7 %

-238.3

-10.729

-9.7

0

-262.2

92.8 %

-237.8

0

-258.81

92.9 %

-234.7

-5.104

50.702

2021-06-30
%

100

0

0

191.06

0

26.836

0

3 608.57

0

-3 608.57

0

5.89

0

0

-3 630.43

0

0

-3 628.5

0

-13.389

271

View Section: Balance Sheet